1 / 4

Cross-border biomarker research of ovarian cancer CrossBiomark (HUSRB/1203/214/091)

Cross-border biomarker research of ovarian cancer CrossBiomark (HUSRB/1203/214/091). Start of Project : 1 st February 2013 End of Project : 31 s t July 2014. The project is co-financed by the European Union. www.hu-srb-ipa.com. Project Partners. University of Szeged (lead beneficiary)

ilar
Download Presentation

Cross-border biomarker research of ovarian cancer CrossBiomark (HUSRB/1203/214/091)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cross-border biomarker research ofovarian cancer CrossBiomark (HUSRB/1203/214/091) Start of Project: 1st February 2013 End of Project: 31st July 2014 The project is co-financed by the European Union www.hu-srb-ipa.com

  2. Project Partners • University of Szeged(lead beneficiary) • Faculty of Medicine • Department of Medical Chemistry • Dr. Róbert Berkecz, PhD. • Tel: 36-62-342-887, e-mail: berkecz.robert@med.u-szeged.hu • Dr. Tamás Janáky, PhD., DSc. • Tel: 36-62-545-137, e-mail: janaky.tamas@med.u-szeged.hu • Prof. Dr. Gábor Tóth, PhD., DSc. • Tel: 36-62-545-139, e-mail: toth.gabor@med.u-szeged.hu • Department of Oncotherapy • Prof. Dr. László Thurzó, PhD., DSc. • Tel: 36-62-545-139, e-mail: thurzo.laszlo@med.u-szeged.hu • University of Novi Sad (project partner) • Medical Faculty • Oncology Institute of Vojvodina • Dr. Aljoša Mandić, PhD. • Tel: +381-21-480-5446, e-mail: aljosa_mandic@yahoo.com The project is co-financed by the European Union www.hu-srb-ipa.com

  3. Project Summary Background Ovarian cancer is the leading cause of death from gynecological malignancies and the fifth major cancer in women in the world. Unfortunately, 70 percent of patients has been diagnosed in late, advanced stage of the disease when the efficacy of the therapy and chance of long-time survival are lower. Early stages of tumors usually can be managed with conventional therapies. Nowadays there are no reliablebiomarkers for early diagnosis of the disease.Currently used biomarkers (CA-125 and HE4) are not good enough for accurate detection of tumors. Aims of the project The overall gols of the project is identificationof new, sensitive and specificblood biomarkers which potentially indicate the appearance of tumors, therefore would help to detect the disease in its early stages. This would enhance the efficacy of the therapy and inrease the chance for long-time survival. Description of work 1. Collection and statistical evaluation of data on epidemiological background of ovarian cancer inSouth Great Plain and Vojvodina regions. 2. Collection of blood samples from patients with different stages of ovarian cancer from both regions. 3. Development of a state of the art analytical chemical method (two-dimensional liquid chromatography-mass spectrometry ( 2D-LC-MS)) for qualitative and quantitative determination of glycero-phospholipid profile in blood. 4. Determination phospholipid profile in healthy women, patients with different stages of ovarian cancer and patients with benign adnexal masses. 5. Identification of putative biomarker panel by biostatistic and bioinformatic evaluation of phospholipid profiles and conventional tumormarkers. The project is co-financed by the European Union www.hu-srb-ipa.com

  4. Expected outputs • The evaluated statistical data will show the distribution of ovarian cancer regarding the age of females and stages of ovarian cancer, and report the tendency of number newly diagnosed patients during the investigated period in South Great Plain and Vojvodina regions.. • A state of the art analytical method (2D-LC-MS/MS) for determination of glycero-phospholipids in blood samples to discover biomarkers for differents diseases.. • Identification of putative phospholipid biomarkers hopefully indicate early stage of ovarian cancer and help two monitor the efficiency of anticancer therapy. • In scienticic proint of view understanding biochemical processes underlying ovarian cancerwould help to develop new medical drug against it. • Establishing long-term scientific cooperation between Universities of Szeged and Novi Sad. IPA funding: 161,976 Eur State contribution: 28,584 Eur This document has been produced with the financial assistance of the European Union. The content of the document is the sole responsibility of Department of Medical Chemistry, Faculty of Medicine at University of Szegedand can under no circumstances be regarded as reflecting the position of the European Union and/or the Managing Authority. The project is co-financed by the European Union www.hu-srb-ipa.com

More Related